Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901.
      Google Scholar   
Citation:
Leuk Lymphoma vol 48 (1) 97-103
Year:
2007
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
Lymphoma
Sec. Committees:
   
Pharmas:
 
Grants:
CA02599, CA04326, CA11789, CA31946, CA33601, CA35113, CA41287, CA47577, CA77406, CA77440, CA77658  
Corr. Author:
 
Authors:
                   
Networks:
 
Study
CALGB-59901
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
Adult, Aged, Antineoplastic Agents, Arabinonucleosides, Disease-Free Survival, Female, Humans, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Male, Middle Aged, Prodrugs, Survival Analysis, Treatment Outcome